

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

updates may be found by visiting the CDC website (1).

References

- 1. www.cdc.gov/od/ohs/lrsat/addinfo.htm
- 2. Federal Register. 42 CFR Part 72,
- Interstate shipment of etiologic agents. Oct. 24, 1996.
- Federal Register. 42 CFR Part 72.6, Additional requirements for facilities transferring or receiving select agents. Oct. 1, 1999.
- National Institutes of Health. Guidelines for research involving recombinant DNA molecules. Federal Register (with subsequent amendments). 59 CFR 34496. July 5, 1995.

Case Report

Necrotizing Enterocolitis in an Infant with Group B Streptococcal Sepsis

J.A. Hervás, M.D.
C. Pérez, M.D.
S. Zibetti, M.D.
M. Fiol, M.D.
C. Galiana, M.D.
Department of Neonatology
Son Dureta University Hospital
Palma de Mallorca, Spain

Necrotizing enterocolitis (NEC) is an entity that mainly affects premature infants but has been described occasionally in full-term neonates (1). The etiologic roles of the infectious agents in this condition are not yet well established, although NEC has been reported in neonates during the course of bacterial, viral, and mycotic infections (2). In this paper, we describe a full-term neonate who developed NEC in the course of sepsis caused by *Streptococcus agalactiae*. To our knowledge, NEC has not been previously reported in association with this microorganism.

Case Report

A female infant weighing 3,300 g was born by forceps delivery after an uneventful 36-week gestation. Amniorrhexis occurred intrapartum and the amniotic fluid was clear. Apgar scores were 6 and 7 at 1 and 5 min, respectively. The infant had respiratory distress that started at birth, and she was transferred to our hospital at 12 h of age. Examination on admission showed an ill-appearing, cyanotic, and poorly perfused newborn who had a blood pressure of 53/36 mm Hg, a pulse of 195 beats/min, and respiratory rate of 84/min. The rectal temperature was 38°C. The infant had respiratory distress and auscultation revealed bilateral hypoventilation and tachycardia. The liver was palpated

4 cm below the right costal margin. She was hypotonic and hypoactive. The anterior fontanelle was flat and there were no meningeal signs.

Laboratory investigation included leukocyte count of 3,100/mm³ with 38% neutrophils, 6% band forms, and 56% lymphocytes. Hemoglobin was 16.7 g/dl; hematocrit, 47.8%; platelet count, 197,000/mm³; Quick test, 44%; and partial thromboplastin time, 68 sec (control 30 sec). Blood urea was 43 mg/dl and creatinine, 1 mg/dl. Arterial blood gases showed severe hypoxemia, hypercapnia, and mixed acidosis. The urine antigen detection test was positive for group B Streptococcus antigen. A blood culture grew group B Streptococcus. The cerebrospinal fluid analysis was normal and its culture was sterile. Culture of a vaginal swab from the mother yielded group B Streptococcus. A chest radiograph revealed a micronodular bilateral alveolar pattern.

Bacterial sepsis was initially suspected and the patient was treated with ampicillin, gentamicin, dopamine, dobutamine, plasma therapy, and mechanical ventilation. Umbilical artery and vein catheterizations were performed. Her condition initially improved but deteriorated again on day 3, and she developed a marked abdominal distention with signs of paralytic ileus. An X ray examination of the abdomen at this time showed a large pneumoperitoneum. After her thrombocytopenia was corrected, a surgical intervention was carried out. At laparotomy, fecal material was found in the abdominal cavity and she had 40 cm of necrotic small bowel. Removal of this loop and a proximal end to distal side anastomosis were performed. The surgical pathology findings showed a congested small bowel with edema, hemorrhage, and ischemic necrosis and wall perforation, compatible with necrotizing enterocolitis. The patient had a complicated postoperative course with dehiscence of the sutures and outward fistulation. On day 22, she underwent surgery again and resection of another 20 cm of necrotic small bowel was required. After this procedure, the patient had a favorable course with mild symptoms of short bowel syndrome.

Comment

NEC mainly occurs in premature infants but has occasionally been reported in full-term neonates. In most of these cases, predisposing factors are usually present. Although our understanding of the pathogenesis of NEC remains incomplete, the disease seems to have a multifactorial basis (3-5). A role of infectious agents as factors or cofactors in the development of some cases of NEC has been proposed. The list of pathogens responsible for NEC has included bacteria (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter, Salmonella, and Clostridium species; coagulasenegative staphylococci, Staphylococcus aureus; Bordetella pertussis), viruses (coxsackie B2, coronavirus, rotavirus, echovirus type 22, cytomegalovirus), and fungi (Candida spp. including albicans, and glabrata) (2).

Although 20 to 30% of patients with NEC may have an associated bacteremia, most likely this represents bacterial translocation through a previously injured intestinal mucosa rather than the primary initiating event (1). The

speculation that a bacterial species can be the primary etiologic factor in the development of NEC, with secondary bacterial translocation from the bowel lumen resulting in septicemia, has not been proven.

The patient that we describe had sepsis and pneumonia caused by group B Streptococcus and had two main factors for the development of NEC: septic shock and umbilical catheterization. Both factors reproduce the ischemichypoxic state that decreases the mesen-

teric blood flow and ultimately causes a hypoxic damage to the enteric mucosa. We have not seen previous mention in the English literature of the association of *S. agalactiae* with NEC; therefore, this report adds a new infectious agent to the list of those associated with this devastating gastrointestinal entity.

References

- Kliegman, R.M. and A.A. Fanaroff, 1984. Necrotizing enterocolitis. N. Engl. J. Med. 310:1093-1103.
- 2. Willughby, R.E. and L.K. Pickering.

- 1994. Necrotizing enterocolitis and infection. Clin. Perinatol. 21:307-315.
- Neu, J. 1996. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr. Clin, N. Am. 43:409-432.
- 4. Albanese, C.T. and M.I. Rowe. 1995. Necrotizing enterocolitis. Semin. Pediatr. Surg. 4:200-206.
- Kliegman, R.M, W.A. Walker, and R.H. Yolken. 1993. Necrotizing enterocolitis: research agenda for a disease of unknown etiology and pathogenesis. Pediatr. Res. 34:701-708.

A Special Invitation to Authors

The editors of Clinical Microbiology Newsletter extend an invitation to authors who may wish to contribute an article or editorial for publication in CMN. Of special interest are timely topics of interest to clinical microbiologists and infectious disease physicians. Persons with suggestions for articles or editorials should contact the Editor listed below to discuss the details of their potential submission.

Paul A. Granato, Ph.D.
Dept. of Microbiology & Immunology
WH 2204
SUNY Upstate Medical University
750 E. Adams St.
Syracuse NY 13210 USA
Tel.: 315-464-7653
e-mail: granatop@upstate.edu

Editors:

Mary Jane Ferraro Paul A. Granato Josephine A. Morello R.J. Zabransky

© 2001 Elsevier Science Inc.

ISSN 0196-4399 CMNEEJ 23(9)67-74, 2001

Elsevier



General Information

Subscription information can be found inside the front cover.

This newsletter has been registered with the Copyright Clearance Center, Inc. Consent is given for copying articles for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition that the copier pay through the Center the per-page fee stated in the code on the first page for copying beyond that permitted by the US Copyright Law. If no code appears on an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

Address orders, changes of address, and claims for missing issues to Journal Fulfillment Department, Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010. Claims for missing issues can be honored only up to three months for domestic addresses and six months for foreign addresses. Duplicate copies will not be sent to replace ones undelivered due to failure to notify Elsevier of change of address.

Postmaster: Send address changes to Clinical Microbiology Newsletter, Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010.

Editorials and letters printed in this newsletter are published for the interest of the readers and do not necessarily reflect the opinions of the editors.

Clinical Microbiology Newsletter is abstracted in Tropical Diseases Bulletin, Abstracts on Hygiene and Communicable Diseases, EMBASE/Excerpta Medica, and Current AIDS Literature.

Full text of this and previous issues can viewed online using the ScienceDirect or ScienceDirect Web-Editions services. Visit http://www.sciencedirect.com or http://www.web-editions.com for more details and access.